Multiple Sclerosis Disease-Modifying Therapies in the COVID-19 Era

John R. Ciotti; Elena Grebenciucova; Brandon P. Moss; Scott D. Newsome

doi:10.1002/ana.25907

Multiple Sclerosis Disease-Modifying Therapies in the COVID-19 Era

John R. Ciotti^*, Elena Grebenciucova, Brandon P. Moss, Scott D. Newsome

^*Corresponding author for this work

Neurology

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Original language	English (US)
Pages (from-to)	1062-1064
Number of pages	3
Journal	Annals of neurology
Volume	88
Issue number	6
DOIs	https://doi.org/10.1002/ana.25907
State	Published - Dec 2020

Funding

J.R.C.: funded by a Sylvia Lawry Physician Fellowship grant, the National Multiple Sclerosis Society; E.G.: nothing to report; B.P.M.: research funding for investigator‐initiated studies, Roche; site Principal Investigator for studies sponsored by Roche; speaking fees, Genzyme; consulting fees, Roche; owns stock, Pfizer; S.D.N.: scientific advisory boards, Biogen, Genentech, Celgene, Novartis, Greenwich Biosciences, EMD Serono; clinical trial clinical adjudication committee member, BioIncept, Autobahn Therapeutics, medDay Pharmaceuticals; grant/research funding (paid directly to institution), Biogen, Genentech, National Multiple Sclerosis Society, Department of Defense, and Patient Centered Outcomes Institute.

ASJC Scopus subject areas

Clinical Neurology
Neurology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/ana.25907

Cite this

@article{0b83c5033da3463abf71a29bb9ae23dd,

title = "Multiple Sclerosis Disease-Modifying Therapies in the COVID-19 Era",

author = "Ciotti, {John R.} and Elena Grebenciucova and Moss, {Brandon P.} and Newsome, {Scott D.}",

note = "Funding Information: J.R.C.: funded by a Sylvia Lawry Physician Fellowship grant, the National Multiple Sclerosis Society; E.G.: nothing to report; B.P.M.: research funding for investigator‐initiated studies, Roche; site Principal Investigator for studies sponsored by Roche; speaking fees, Genzyme; consulting fees, Roche; owns stock, Pfizer; S.D.N.: scientific advisory boards, Biogen, Genentech, Celgene, Novartis, Greenwich Biosciences, EMD Serono; clinical trial clinical adjudication committee member, BioIncept, Autobahn Therapeutics, medDay Pharmaceuticals; grant/research funding (paid directly to institution), Biogen, Genentech, National Multiple Sclerosis Society, Department of Defense, and Patient Centered Outcomes Institute.",

year = "2020",

month = dec,

doi = "10.1002/ana.25907",

language = "English (US)",

volume = "88",

pages = "1062--1064",

journal = "Annals of neurology",

issn = "0364-5134",

publisher = "John Wiley & Sons Inc.",

number = "6",

}

TY - JOUR

T1 - Multiple Sclerosis Disease-Modifying Therapies in the COVID-19 Era

AU - Ciotti, John R.

AU - Grebenciucova, Elena

AU - Moss, Brandon P.

AU - Newsome, Scott D.

N1 - Funding Information: J.R.C.: funded by a Sylvia Lawry Physician Fellowship grant, the National Multiple Sclerosis Society; E.G.: nothing to report; B.P.M.: research funding for investigator‐initiated studies, Roche; site Principal Investigator for studies sponsored by Roche; speaking fees, Genzyme; consulting fees, Roche; owns stock, Pfizer; S.D.N.: scientific advisory boards, Biogen, Genentech, Celgene, Novartis, Greenwich Biosciences, EMD Serono; clinical trial clinical adjudication committee member, BioIncept, Autobahn Therapeutics, medDay Pharmaceuticals; grant/research funding (paid directly to institution), Biogen, Genentech, National Multiple Sclerosis Society, Department of Defense, and Patient Centered Outcomes Institute.

PY - 2020/12

Y1 - 2020/12

UR - http://www.scopus.com/inward/record.url?scp=85091724611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85091724611&partnerID=8YFLogxK

U2 - 10.1002/ana.25907

DO - 10.1002/ana.25907

M3 - Article

C2 - 32951235

AN - SCOPUS:85091724611

SN - 0364-5134

VL - 88

SP - 1062

EP - 1064

JO - Annals of neurology

JF - Annals of neurology

IS - 6

ER -

Multiple Sclerosis Disease-Modifying Therapies in the COVID-19 Era

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this